Exosome Therapy Market by Type of Therapeutic, Target Indication, Therapeutic Area, Route of Administration and Geography : Industry Trends and Global Forecasts, Till 2035

List of Tables

EXOSOME THERAPY MARKET: OVERVIEW

As per Roots Analysis, the global exosome therapy is estimated to grow from USD 0.03 billion in 2029 to USD 1.4 billion by 2040, at a CAGR of 41.1% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Exosome Therapeutics

Allogenic
Autologous

Target Disease Indications

Degenerative Meniscal Injury
Dystrophic Epidermolysis Bullosa
Fistula Perianal
Retinitis Pigmentosa

Therapeutic Area

Dermatological Disorders
Musculoskeletal Disorders
Ophthalmic Disorders
Rectal Disorders

Route of Administration

Fistula Tract
Intra-articular
Intra-ocular

Key Geographical Regions

North America
Europe
Asia-Pacific
Rest of the World

EXOSOME THERAPY MARKET: GROWTH AND TRENDS

Owing to the various benefits, such as enhanced tissue regeneration, reduced inflammation and chronic pain, and target specificity, exosome therapies have garnered significant attention in the recent past. Various studies have demonstrated the high efficacy and therapeutic superiority of exosome therapeutics in disease diagnosis, drug delivery and therapeutic applications. It is worth highlighting that over 120 therapeutic candidates are currently being investigated for treating myriads of disease indications, across the globe. This depicts the extensive development efforts being undertaken by drug developers in this domain. More than 40% of the total number of drugs are in various phases of clinical development. Of the total candidates, seven exosome therapies, including EXOMSC-COV19 (Dermama Biotech Lab), Dex2 (Gustave Roussy Institute), SF-MSC-EX (Osmangazi University), are currently being tested in the advanced clinical stages of development.

At present, around 30% of exosome-based therapeutics are under development for the treatment of various cancers. This innovative approach uses exosomes as a means to deliver drugs specifically to cancer cells, and these therapies are still in the early phases of research. Notable types of cancer being investigated for exosome delivery systems include breast cancer, lung cancer, melanoma, and colon cancer. Considering the ongoing R&D efforts in this domain, promising clinical trial results and anticipated launch of late-stage exosome therapies, the market is anticipated to witness notable growth over the next decade.

EXOSOME THERAPY MARKET: KEY INSIGHTS

The report delves into the current state of the exosome therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Close to 60 players, worldwide, have taken initiatives to develop exosome therapeutics; the market is characterized by the presence of start-ups and small companies.

The current pipeline features more than 120 exosome therapeutics that are being evaluated across different phases of development; most of these are designed for intravenous administration.
3,000+ patients have been recruited / enrolled in clinical trials evaluating exosome related therapies and biomarkers across different geographies.
More than 530 grants have been awarded for the ongoing R&D efforts for exosome therapeutics; the University of California has been awarded the maximum grant amount of USD 21 million.
A variety of investors, having realized the benefits and future opportunities in this field, have invested more than USD 570 million across more than 30 instances.
The rising interest of stakeholders in exosome therapeutics is also reflected by the increasing number of partnerships established by various industry and non-industry players.
Stakeholders have participated in various global events to discuss the research outcomes, and affiliated challenges as well as opportunities existing in this domain.
At present, more than 30 start-ups are driving innovation in this domain; a variety of R&D initiatives have been undertaken by these players over the last few years for the development of exosome therapeutics.
Lack of efficacy, the COVID-19 pandemic, limited patient enrollment, and scarce funding are among the key reasons that have led to the discontinuation of studies sponsored by various industry and non-industry players.
With the rising demand for therapeutic advances in drug safety, the market for exosome therapeutics is expected to grow at an annualized rate of 41.1% between 2029-2040.

EXOSOME THERAPY MARKET: KEY SEGMENTS

Autologous Therapies are Likely to Capture Largest Share of the Exosome Therapy Market

Based on the type of therapy, the market is segmented into allogenic therapy and autologous therapy. It is anticipated that the autologous therapy segment will hold the maximum share of the exosome therapy market in 2029. However, it is worth highlighting that allogeneic therapy is likely to grow at a relatively higher CAGR.

Retinitis Pigmentosa is Likely to be the Fastest Growing Segment of the Exosome Therapy Market During the Forecast Period

Based on the target disease indication, the market is segmented into degenerative meniscal injury, dystrophic epidermolysis bullosa, fistula perianal and retinitis pigmentosa. It is anticipated that fistula perianal will hold the maximum share of the exosome therapy market in 2029. However, it is worth highlighting that the exosome therapy market for retinitis pigmentosa is likely to grow at a relatively higher CAGR.

Rectal Disorders Segment is the Fastest Growing Segment of the Exosome Therapy Market

Based on the therapeutic area, the market is segmented into dermatological disorders, musculoskeletal disorders, ophthalmic disorders and rectal disorders. While the rectal disorders segment is likely to hold a relatively higher market share, it is worth highlighting that the ophthalmic diseases segment is expected to witness substantial market growth in the coming years.

Fistula Tract Segment is Likely to Capture Largest Share of the Exosome Therapy Market in 2029

Based on the route of administration, the market is segmented into fistula tract, intra-articular and intra-ocular. It is anticipated that the fistula tract segment will hold the maximum share of the exosome therapy market in 2029. However, it is worth highlighting that the intraocular segment is likely to grow at a relatively higher CAGR.

Asia-Pacific Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and the Rest of the World. The majority share is expected to be captured by drug developers based in Asia-Pacific. It is worth highlighting that, over the years, the market in Europe is expected to grow at a higher CAGR.

Example Players in the Exosome Therapy Market

Coya Therapeutics
Evox Therapeutics
Curexsys
EV Therapeutics
SHIFTBIO

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Chief Business Officer, Capricor Therapeutics
R&D and Innovation Manager, Exogenus Therapeutics
Chief Business Officer, ILIAS Biologics

EXOSOME THERAPY MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the exosome therapy market, focusing on key market segments, including [A] type of therapy, [B] target disease indications, [C] therapeutic area, [D] route of administration and [E] key geographical regions.
Market Landscape: A comprehensive evaluation of exosome therapeutics, considering various parameters, such as [A] phase of development, [B] technology platform, [C] type of payload, [D] target disease indication (s), [E] therapeutic area, [F] biological target, [G] route of administration, [H] type of therapy, [I] combination drug, [J] line of treatment and [K] dosing frequency. Further, it includes details on the exosome therapeutic developers, along with information on their [L] year of establishment, [M] company size and [N] location of headquarters.
Company Profiles: In-depth profiles of key industry players engaged in the development of exosome therapeutics, focusing on [A] company overviews, [B] financial information (if available), [C] product portfolio, [E] recent developments and [F] an informed future outlook.
Drug Profiles: In-depth profiles of key exosome therapies, focusing on [A] product portfolio and [B] clinical trial information.
Clinical Trials Analysis: Examination of completed, ongoing, and planned clinical studies of various exosome therapeutics, based on parameters like [A] trial status, [B] trial registration year, [C] type of sponsor / collaborator, [D] study design, [E] number of patients enrolled, [F] year-wise trend of completed and recruiting trials, [G] age group of the patients enrolled, [H] active industry and non-industry players and [I] location of the trials.
Academic Grant Analysis: A comprehensive examination of various academic grants that have been awarded to various research institutes for projects related to exosome therapeutics, based on several parameters, such as [A] year of grant awarded, [B] amount awarded, [C] type of funding institute center, [D] popular NIH departments, [E] support period, [F] emerging focus area, [G] purpose of grants, [H] grant activity code, [I] local recipients, [J] type of recipient organization study section, [K] type of grant application and [L] popular recipient organizations, (in terms of number of grants and amount awarded).
Global Event Analysis: An in-depth analysis of the global events attended by the exosome therapy developers, based on several relevant parameters, such as [A] year of event, [B] type of event platform, [C] location of event, [D] emerging focus areas, [E] active organizers (in terms of number of events), [F] active industry and non-industry participants, [G] designation of participants, [H] affiliated department of participants, and [I] active speakers (in terms of number of events).
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2017, covering research agreements, licensing agreements, manufacturing agreements, product development and commercialization agreements, mergers / acquisitions, and other relevant deals.
Funding and Investment Analysis: A detailed evaluation of the investments made in this domain, encompassing seed financing, venture capital financing, IPOs, secondary offering, debt financing and other equity.
Start-Up Health Indexing: An analysis of start-ups / small companies engaged in the development of exosome therapeutics, based on parameters, such as [A] pipeline strength, [B] pipeline maturity, [C] financial support, [D] number of investors, [E] partnership activity and [F] start-up health indexing.
Case Study: A case study highlighting the companies offering development and manufacturing services for exosome therapeutics, along with the information on their [A] year of establishment, [B] company size, [C] location of headquarters, [D] types of service(s) offered, [E] method of isolation, [F] method of purification, [G] method of characterization, [H] method of exosome manufacturing, [I] scale of operation and [J] scalability.
Drug Failure Analysis: An in-depth analysis, focusing on exosome therapeutics that failed to progress to later stages of clinical development, based on various relevant parameters, such as [A] trial status of discontinuation, [B] target disease indication(s), [C] route of administration and [D] type of sponsor.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100394

1. PREFACE

1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of Exosomes
- 3.1.1. Types of Extracellular Vesicles
- 3.1.2. Potential Sources of Exosomes
3.2. Exosome Biogenesis
- 3.2.1. Exosome Formation and Development Process
- 3.2.2. Secretion of Exosomes
3.3. Applications of Exosomes
3.4. Mechanism of Exosome Therapy
- 3.4.1. Exosome Drug Therapy
- 3.4.2. Exosome RNAi Therapy
- 3.4.3. Exosome Immunotherapy
3.5. Advantages of Exosome Therapies
3.6. Risks and Future Perspectives Associated with Exosome Therapeutics

4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE

4.1. Analysis Methodology and Key Parameters
4.2. Exosome Therapeutics Market Landscape
- 4.2.1. Analysis by Phase of Development
- 4.2.2. Analysis by Technology Platform
- 4.2.3. Analysis by Type of Payload
- 4.2.4. Analysis by Type of Formulation
- 4.2.5. Analysis by Type of Therapy
- 4.2.6. Analysis by Derived Source
- 4.2.7. Analysis by Target Disease Indication(s)
- 4.2.8. Analysis by Therapeutic Area
- 4.2.9. Analysis by Phase of Development and Therapeutic Area
- 4.2.10. Analysis by Route of Administration
- 4.2.11. Analysis by Therapeutic Area and Route of Administration
- 4.2.12. Analysis by Type of Therapy (By Method of Composition)
- 4.2.13. Analysis by Line of Treatment
- 4.2.14. Analysis by Dosing Frequency
4.3. Exosome Therapeutics Developers
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters
- 4.3.4. Most Active Players: Analysis by Number of Therapeutics

5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES

5.1. Codiak BioSciences
- 5.1.1. Company Overview
- 5.1.2. Product Portfolio
- 5.1.3. Clinical Trial Information
- 5.1.4. Recent Developments and Future Outlook
5.2. Coya Therapeutics
- 5.2.1. Company Overview
- 5.2.2. Product Portfolio
- 5.2.3. Recent Developments and Future Outlook
5.3. Curexsys
- 5.3.1. Company Overview
- 5.3.2. Product Portfolio
- 5.3.3. Recent Developments and Future Outlook
5.4. EV Therapeutics
- 5.4.1. Company Overview
- 5.4.2. Product Portfolio
- 5.4.3. Recent Developments and Future Outlook
5.5. Evox Therapeutics
- 5.5.1. Company Overview
- 5.5.2. Product Portfolio
- 5.5.3. Recent Developments and Future Outlook
5.6. SHIFTBIO
- 5.6.1. Company Overview
- 5.6.2. Product Portfolio
- 5.6.3. Recent Developments and Future Outlook

6. EXOSOME THERAPEUTICS: DRUG PROFILES

6.1. AEGLE Therapeutics
- 6.1.1. Company Overview
- 6.1.2. AGLE-102: Product Portfolio
  - 6.1.2.1. AGLE-102: Clinical Trial Information
- 6.1.3. Recent Developments and Future Outlook
6.2. AVEM Healthcare
- 6.2.1. Company Overview
- 6.2.2. Ardoxso: Product Portfolio
  - 6.2.2.1. Ardoxso: Clinical Trial Information
- 6.2.3. Recent Developments and Future Outlook
6.3. Cellular Biomedicine Group
- 6.3.1. Company Overview
- 6.3.2. Financial Information
- 6.3.3. haMPC-Exos: Product Portfolio
  - 6.3.3.1. haMPC-Exos: Clinical Trial Information
- 6.3.4. hMSC-Exos: Product Portfolio
  - 6.3.4.1. hMSC-Exos: Clinical Trial Information
- 6.3.5. Undisclosed Drug 1: Product Portfolio
  - 6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
- 6.3.6. Recent Developments and Future Outlook
6.4. OBCTCD24
- 6.4.1. Company Overview
- 6.4.2. CovenD24: Product Portfolio
  - 6.4.2.1. CovenD24: Clinical Trial Information
- 6.4.3. Recent Developments and Future Outlook
6.5. ReNeuron
- 6.5.1. Company Overview
- 6.5.2. Financial Information
- 6.5.3. Undisclosed Drug 1: Product Portfolio
  - 6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
- 6.5.4. Recent Developments and Future Outlook
6.6. Stem Cell Medicine
- 6.6.1. Company Overview
- 6.6.2. Undisclosed Drug 1: Product Portfolio
- 6.6.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

7.1. Analysis Methodology and Key Parameters
7.2. Exosome Therapeutics: List of Clinical Trials
- 7.2.1. Analysis by Trial Status
- 7.2.2. Analysis by Trial Registration Year
- 7.2.3. Analysis by Type of Sponsor / Collaborator
- 7.2.4. Analysis by Registration Year and Type of Study
- 7.2.5. Analysis by Registration Year and Status of Trial
- 7.2.6. Analysis by Study Design
- 7.2.7. Analysis by Patient Enrollment
- 7.2.8. Year-wise Trend of Completed and Recruiting Trials
- 7.2.9. Analysis by Age Category
- 7.2.10. Analysis by Phase of Development and Trial Status
- 7.2.11. Analysis by Phase of Development and Patient Enrollment
- 7.2.12. Most Active Industry Players: Analysis by Number of Registered Trials
- 7.2.13. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 7.2.14. Analysis by Trial Location
- 7.2.15. Analysis by Trial Status and Geography

8. ACADEMIC GRANT ANALYSIS

8.1. Analysis Methodology and Key Parameters
8.2. Exosome Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded
8.5. Popular NIH Departments: Analysis by Number of Grants
8.6. Analysis by Type of Funding Institute Center
8.7. Analysis by Support Period
8.8. Analysis by Purpose of Grants
8.9. Word Cloud Analysis: Emerging Focus Area
8.10. Analysis by Grant Activity Code
8.11. Analysis by Local Recipients
8.12. Analysis by Type of Recipient Organization
8.13. Popular Recipient Organizations: Analysis by Amount Awarded
8.14. Popular Recipient Organizations: Analysis by Number of Grants
8.15. Analysis by Study Section Involved
8.16. Analysis by Type of Grant Application
8.17. Analysis by Funding Institute Center and Support Year

9. GLOBAL EVENT ANALYSIS

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
- 9.3.1. Analysis by Year of Event
- 9.3.2. Analysis by Event Platform
- 9.3.3. Analysis by Type of Event
- 9.3.4. Analysis by Location of Event
- 9.3.5. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
- 9.3.6. Most Active Organizers: Analysis by Number of Events
- 9.3.7. Most Active Industry Participants: Analysis by Number of Events
- 9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
- 9.3.9. Analysis by Designation of Participant
- 9.3.10. Analysis by Affiliated Department of Participant
- 9.3.11. Most Active Speakers: Analysis by Number of Events

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview
10.2. Partnership Models
10.3. Exosome Therapeutics: List of Partnerships and Collaborations
- 10.3.1. Analysis by Year of Partnership
- 10.3.2. Analysis by Type of Partnership
- 10.3.3. Analysis by Year and Type of Partnership
- 10.3.4. Analysis by Company and Type of Partnership
- 10.3.5. Analysis by Type of Technology Platform
- 10.3.6. Analysis by Type of Partner
- 10.3.7. Word Cloud Analysis: Emerging Focus Areas
- 10.3.8. Analysis by Target Disease Indication(s)
- 10.3.9. Analysis by Therapeutic Area
- 10.3.10. Analysis by Therapeutic Area and Type of Partnership
- 10.3.11. Most Active Players: Analysis by Number of Partnerships
- 10.3.12. Regional Analysis
- 10.3.13. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS

11.1. Analysis Methodology and Key Parameters
11.2. Type of Funding
11.3. Exosome Therapeutics: List of Funding Instances
11.4. Analysis by Year of Funding
11.5. Analysis by Amount Invested
11.6. Analysis by Type of Funding
11.7. Analysis by Type of Funding and Amount Invested
11.8. Analysis by Year, Type of Funding and Amount Invested
11.9. Analysis by Purpose of Funding
11.10. Analysis by Target Disease Indication(s)
11.11. Analysis by Therapeutic Area
11.12. Most Active Players: Analysis by Number of Funding Instances
11.13. Most Active Players: Analysis by Amount Invested
11.14. Key Investors: Analysis by Number of Funding Instances
11.15. Regional Analysis
11.16. Summary of Funding Instances

12. START-UP HEALTH INDEXING

12.1. Analysis Methodology and Key Parameters
12.2. Analysis by Pipeline Maturity
12.3. Analysis by Pipeline Strength
12.4. Analysis by Financial Support
12.5. Analysis by Number of Investors
12.6. Analysis by Partnership Activity
12.7. Start-up Health Indexing: Roots Analysis Perspective

13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS

13.1. Chapter Overview
13.2. Exosome Development and Manufacturing Service Providers Landscape
- 13.2.1. Analysis by Year of Establishment
- 13.2.2. Analysis by Company Size
- 13.2.3. Analysis by Location of Headquarters
- 13.2.4. Analysis by Location of Headquarters and Company Size
13.3. Analysis by Type of Service(s) Offered
- 13.3.1. Analysis by Method of Isolation
- 13.3.2. Analysis by Method of Purification
- 13.3.3. Analysis by Method of Characterization
- 13.3.4. Analysis by Method of Exosome Manufacturing
- 13.3.5. Analysis by Scale of Operation
- 13.3.6. Analysis by Scalability

14. DRUG FAILURE ANALYSIS

14.1. Methodology and Key Parameters
14.2. Exosome Therapeutics: List of Failed Drug Candidates
- 14.2.1. Analysis by Study Start Year and Year of Termination of the Clinical Trials
- 14.2.2. Analysis by Trial Status of Discontinuation
- 14.2.3. Analysis by Target Disease Indication(s)
- 14.2.4. Analysis by Route of Administration
- 14.2.5. Analysis by Type of Sponsor
- 14.2.6. Analysis by Reasons for Drug Failure
- 14.2.7. Word Cloud Analysis: Emerging Focus Area

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

15.1. Forecast Methodology and Key Assumptions
15.2. Global Exosome Therapeutics Market, 2029-2040
15.3. Global Exosome Therapeutics Market, 2029-2040: Distribution by Target Disease Indication(s)
- 15.3.1. Exosome Therapeutics Market for COVID-19, 2029-2040
- 15.3.2. Exosome Therapeutics Market for Degenerative Meniscal Injury, 2029-2040
- 15.3.3. Exosome Therapeutics Market for Retinitis Pigmentosa, 2029-2040
15.4. Global Exosome Therapeutics Market, 2029-2040: Distribution by Therapeutic Area
- 15.4.1. Exosome Therapeutics Market for Infectious Diseases, 2029-2040
- 15.4.2. Exosome Therapeutics Market for Ophthalmic Diseases, 2029-2040
- 15.4.3. Exosome Therapeutics Market for Musculoskeletal Disorders, 2029-2040
15.5. Global Exosome Therapeutics Market, 2029-2040: Distribution by Route of Administration
- 15.5.1. Intravenous Exosome Therapeutics Market, 2029-2040
- 15.5.2. Intra-ocular Exosome Therapeutics Market, 2029-2040
- 15.5.3. Intra-articular Exosome Therapeutics Market, 2029-2040
- 15.5.4. Inhalation Exosome Therapeutics Market, 2029-2040
15.6. Global Exosome Therapeutics Market, 2029-2040: Distribution by Type of Formulation
- 15.6.1. Exosome Therapeutics Market for Liquid Formulations, 2029-2040
- 15.6.2. Exosome Therapeutics Market for Aerosol Formulations, 2029-2040
15.7. Global Exosome Therapeutics Market, 2029-2040: Distribution by Geography
- 15.7.1. Exosome Therapeutics Market in North America, 2029-2040
- 15.7.2. Exosome Therapeutics Market in Europe, 2029-2040
- 15.7.3. Exosome Therapeutics Market in Asia Pacific, 2030-2040
15.8. Attractiveness and Competitiveness Matrix

16. EXECUTIVE INSIGHTS

16.1. Capricor Therapeutics
- 16.1.1. Company Snapshot
- 16.1.2. Interview Transcript: Chief Business Officer
16.2. Exogenus Therapeutics
- 16.2.1. Company Snapshot
- 16.2.2. Interview Transcript: R&D and Innovation Manager
16.3. ILIAS Biologics
- 16.3.1. Company Snapshot
- 16.3.2. Interview Transcript: Chief Business Officer

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100394

List of Tables

Table 4.1 Exosome Therapeutics: Development Pipeline
Table 4.2 Exosome Therapeutics: List of Developers
Table 5.1 Codiak BioSciences: Product Portfolio
Table 5.2 Codiak BioSciences: Clinical Trial Information
Table 5.3 Recent Developments and Future Outlook
Table 5.4 Coya Therapeutics: Product Portfolio
Table 5.5 Recent Developments and Future Outlook
Table 5.6 Curexsys: Product Portfolio
Table 5.7 Recent Developments and Future Outlook
Table 5.8 EV Therapeutics: Product Portfolio
Table 5.9 Recent Developments and Future Outlook
Table 5.10 Evox Therapeutics: Product Portfolio
Table 5.11 Recent Developments and Future Outlook
Table 5.12 SHIFTBIO: Product Portfolio
Table 5.13 Recent Developments and Future Outlook
Table 6.1 AGLE-102: Product Portfolio
Table 6.2 AGLE-102: Clinical Trial Information
Table 6.3 Ardoxso: Product Portfolio
Table 6.4 Ardoxso: Clinical Trial Information
Table 6.5 Recent Developments and Future Outlook
Table 6.6 haMPC-Exos: Product Portfolio
Table 6.7 haMPC-Exos: Clinical Trial Information
Table 6.8 hMSC-Exos: Product Portfolio
Table 6.9 hMSC-Exos: Clinical Trial Information
Table 6.10 Undisclosed Drug 1: Product Portfolio
Table 6.11 Undisclosed Drug 1: Clinical Trial Information
Table 6.12 Recent Developments and Future Outlook
Table 6.13 CovenD24: Product Portfolio
Table 6.14 CovenD24: Clinical Trial Information
Table 6.15 Undisclosed Drug 1: Product Portfolio
Table 6.16 Undisclosed Drug 1: Clinical Trial Information
Table 6.17 Recent Developments and Future Outlook
Table 6.18 Undisclosed Drug 1: Product Portfolio
Table 7.1 Exosome Therapeutics: List of Clinical Trials, since 2017
Table 8.1 Exosome Therapeutics: List of Grants Awarded
Table 9.1 Exosome Therapeutics: List of Global Events, since 2017
Table 10.1 Exosome Therapeutics: List of Partnerships and Collaborations, since 2017
Table 11.1 Exosome Therapeutics: List of Funding and Investment, since 2017
Table 12.1 Exosome Therapeutics: List of Start-Ups, since 2017
Table 13.1 Case Study: List of Exosome Service Providers
Table 17.1 Exosome Therapeutics Market: Distribution by Phase of Development
Table 17.2 Exosome Therapeutics Market: Distribution by Technology Platform
Table 17.3 Exosome Therapeutics Market: Distribution by Type of Payload
Table 17.4 Exosome Therapeutics Market: Distribution by Type of Formulation
Table 17.5 Exosome Therapeutics Market: Distribution by Type of Therapy
Table 17.6 Exosome Therapeutics Market: Distribution by Derived Source
Table 17.7 Exosome Therapeutics Market: Distribution by Target Disease Indication(s)
Table 17.8 Exosome Therapeutics Market: Distribution by Therapeutic Area
Table 17.9 Exosome Therapeutics Market: Distribution by Phase of Development and
Table 17.10 Exosome Therapeutics Market: Distribution by Route of Administration
Table 17.11 Exosome Therapeutics: Distribution by Therapeutic Area and Route of Administration
Table 17.12 Exosome Therapeutics Market: Distribution by Type of Therapy (By method of composition)
Table 17.13 Exosome Therapeutics Market: Distribution by Line of Treatment
Table 17.14 Exosome Therapeutics Market: Distribution by Dosing Frequency
Table 17.15 Exosome Therapeutics Developers: Distribution by Year of Establishment
Table 17.16 Exosome Therapeutics Developers: Distribution by Company Size
Table 17.17 Exosome Therapeutics Developers: Distribution by Location of Headquarters
Table 17.18 Most Active Players: Distribution by Number of Exosome Therapeutics
Table 17.19 Cellular Biomedicine Group: Financial Information, FY 2015 Onwards (USD Million)
Table 17.20 ReNeuron: Financial Information, FY 2018 Onwards (USD Million)
Table 17.21 Clinical Trials Analysis: Distribution by Trial Status
Table 17.22 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year
Table 17.23 Clinical Trials Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.24 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study
Table 17.25 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial
Table 17.26 Clinical Trials Analysis: Distribution by Study Design
Table 17.27 Clinical Trials Analysis: Distribution by Patient Enrollment
Table 17.28 Clinical Trials Analysis: Year-wise Trend of Completed and Recruiting Trials
Table 17.29 Clinical Trials Analysis: Distribution by Age Category
Table 17.30 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
Table 17.31 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
Table 17.32 Most Active Industry Players: Distribution by Number of Registered Trials
Table 17.33 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 17.34 Clinical Trials Analysis: Distribution by Trial Location
Table 17.35 Clinical Trials Analysis: Distribution by Trial Status and Geography
Table 17.36 Academic Grant Analysis: Year-wise Distribution of Number of Grants
Table 17.37 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded (USD Million)
Table 17.38 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
Table 17.39 Academic Grant Analysis: Analysis by Type of Funding Institute Center
Table 17.40 Academic Grant Analysis: Distribution by Support Period
Table 17.41 Academic Grant Analysis: Distribution by Purpose of Grants
Table 17.42 Academic Grant Analysis: Distribution by Grant Activity Code
Table 17.43 Academic Grant Analysis: Distribution by Local Recipients
Table 17.44 Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 17.45 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount Awarded (USD Million)
Table 17.46 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number of Grants
Table 17.47 Academic Grant Analysis: Distribution by Study Section
Table 17.48 Academic Grant Analysis: Distribution by Type of Grant Application
Table 17.49 Academic Grant Analysis: Analysis by Funding Institute Center and Support Year
Table 17.50 Global Events: Cumulative Half Yearly Trend, since 2017
Table 17.51 Global Events: Distribution by Event Platform
Table 17.52 Global Events: Distribution by Type of Event
Table 17.53 Global Events: Distribution by Location of Event
Table 17.54 Most Active Organizers: Distribution by Number of Events
Table 17.55 Most Active Industry Participants: Distribution by Number of Events
Table 17.56 Most Active Non-Industry Participants: Distribution by Number of Events
Table 17.57 Global Events: Distribution by Designation of Participant
Table 17.58 Global Events: Distribution by Affiliated Department of Participant
Table 17.59 Most Active Speakers: Distribution by Number of Events
Table 17.60 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2017
Table 17.61 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.62 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, since 2017
Table 17.63 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, since 2017
Table 17.64 Partnerships and Collaborations: Distribution by Type of Technology Platform
Table 17.65 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.66 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Table 17.67 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.68 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Table 17.69 Most Active Players: Distribution by Number of Partnerships
Table 17.70 Partnerships and Collaborations: Regional Distribution
Table 17.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 17.72 Funding and Investments: Year-wise Distribution by Year of Funding, since 2017
Table 17.73 Funding and Investments: Year-wise Distribution by Amount Invested, since 2017
Table 17.74 Funding and Investments: Distribution by Type of Funding
Table 17.75 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, since 2017
Table 17.76 Funding and Investments: Year-wise Distribution by Year, Type of Funding and Amount Invested, since 2017
Table 17.77 Funding and Investments: Distribution by Purpose of Funding
Table 17.78 Funding and Investments: Distribution by Target Disease Indication(s)
Table 17.79 Funding and Investments: Distribution by Therapeutic Area
Table 17.80 Most Active Players: Distribution by Number of Funding Instances
Table 17.81 Most Active Players: Distribution by Amount Invested (USD Million)
Table 17.82 Key Investors: Distribution by Number of Funding Instances
Table 17.83 Funding and Investments: Regional Distribution of Instances
Table 17.84 Start-up Health Indexing: Distribution by Pipeline Maturity
Table 17.85 Start-up Health Indexing: Distribution by Pipeline Strength
Table 17.86 Start-up Health Indexing: Distribution by Financial Support
Table 17.87 Start-up Health Indexing: Distribution by Partnership Activity
Table 17.88 Case Study: Distribution of Exosome Service Providers by Year of Establishment
Table 17.89 Case Study: Distribution of Exosome Service Providers by Company Size
Table 17.90 Case Study: Distribution of Exosome Service Providers by Location of Headquarters
Table 17.91 Case Study: Distribution of Exosome Service Providers by Location of Headquarters and Company Size
Table 17.92 Case Study: Distribution of Exosome Service Providers by Type of Service(s) Offered
Table 17.93 Case Study: Distribution of Exosome Service Providers by Method(s) of Isolation
Table 17.94 Case Study: Distribution of Exosome Service Providers by Method(s) of Purification
Table 17.95 Case Study: Distribution of Exosome Service Providers by Method(s) of Characterization
Table 17.96 Case Study: Distribution of Exosome Service Providers by Method(s) of Exosome Manufacturing
Table 17.97 Case Study: Distribution of Exosome Service Providers by Scale of Operation
Table 17.98 Case Study: Distribution of Exosome Service Providers by Scalability
Table 17.99 Drug Failure Analysis: Distribution by Study Start Year and Year of Termination of the Clinical Trials
Table 17.100 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
Table 17.101 Drug Failure Analysis: Distribution by Target Disease Indication(s)
Table 17.102 Drug Failure Analysis: Distribution by Route of Administration
Table 17.103 Drug Failure Analysis: Distribution by Type of Sponsor
Table 17.104 Drug Failure Analysis: Distribution by Reasons for Drug Failure
Table 17.105 Drug Failure Analysis: Other Plausible Reasons for Drug Failure
Table 17.106 Global Exosome Therapeutics Market, 2029 and 2035: Distribution by Therapeutic Area (USD Million)
Table 17.107 Exosome Therapeutics Market for Infectious Diseases, 2029-2040 (USD Million)
Table 17.108 Exosome Therapeutics Market for Musculoskeletal Disorders, 2029-2040 (USD Million)
Table 17.109 Exosome Therapeutics Market for Ophthalmic Diseases, 2033-2040 (USD Million)
Table 17.110 Global Exosome Therapeutics Market, 2029 and 2035: Distribution by Route of Administration
Table 17.111 Inhalation Exosome Therapeutics Market, 2029-2040 (USD Million)
Table 17.112 Intravenous Exosome Therapeutics Market, 2031-2040 (USD Million)
Table 17.113 Intra-articular Exosome Therapeutics Market, 2033-2040 (USD Million)
Table 17.114 Intra-ocular Exosome Therapeutics Market, 2029-2040 (USD Million)
Table 17.115 Global Exosome Therapeutics Market, 2029 and 2035: Distribution by Type of Formulation
Table 17.116 Exosome Therapeutics Market for Liquid Formulations, 2029-2040 (USD Million)
Table 17.117 Exosome Therapeutics Market for Aerosol Formulations, 2029-2040 (USD Million)
Table 17.118 Global Exosome Therapeutics Market, 2029 and 2035: Distribution by Geography
Table 17.119 Exosome Therapeutics Market in North America, 2029-2040 (USD Million)
Table 17.120 Exosome Therapeutics Market in Europe, 2029-2040 (USD Million)
Table 17.121 Exosome Therapeutics Market in Asia Pacific, 2030-2040 (USD Million)

List of Figures

Figure 3.1 Potential Sources of Exosomes
Figure 3.2 Secretion of Exosomes
Figure 3.3 Mechanism of Exosome Therapy
Figure 4.1 Exosome Therapeutics Market: Distribution by Phase of Development
Figure 4.2 Exosome Therapeutics Market: Distribution by Technology Platform
Figure 4.3 Exosome Therapeutics Market: Distribution by Type of Payload
Figure 4.4 Exosome Therapeutics Market: Distribution by Type of Formulation
Figure 4.5 Exosome Therapeutics Market: Distribution by Type of Therapy
Figure 4.6 Exosome Therapeutics Market: Distribution by Derived Source
Figure 4.7 Exosome Therapeutics Market: Distribution by Target Disease Indication(s)
Figure 4.8 Exosome Therapeutics Market: Distribution by Therapeutic Area
Figure 4.9 Exosome Therapeutics Market: Distribution by Phase of Development and Therapeutic Area
Figure 4.10 Exosome Therapeutics Market: Distribution by Route of Administration
Figure 4.11 Exosome Therapeutics: Distribution by Therapeutic Area and Route of Administration
Figure 4.12 Exosome Therapeutics Market: Distribution by Type of Therapy (By method of composition)
Figure 4.13 Exosome Therapeutics Market: Distribution by Line of Treatment
Figure 4.14 Exosome Therapeutics Market: Distribution by Dosing Frequency
Figure 4.15 Exosome Therapeutics Developers: Distribution by Year of Establishment
Figure 4.16 Exosome Therapeutics Developers: Distribution by Company Size
Figure 4.17 Exosome Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.18 Exosome Therapeutics Developers: Most Active Players: Distribution by Number of Therapeutic Programs
Figure 6.1 Cellular Biomedicine Group: Financial Information, FY 2015 Onwards (USD Million)
Figure 6.2 ReNeuron: Financial Information, FY 2018 Onwards (USD Million)
Figure 7.1 Clinical Trials Analysis: Distribution by Trial Status
Figure 7.2 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year
Figure 7.3 Clinical Trials Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.4 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study
Figure 7.5 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial
Figure 7.6 Clinical Trials Analysis: Distribution by Study Design
Figure 7.7 Clinical Trials Analysis: Distribution by Patient Enrollment
Figure 7.8 Clinical Trials Analysis: Year-wise Trend of Completed and Recruiting Trials
Figure 7.9 Clinical Trials Analysis: Distribution by Age Group
Figure 7.10 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
Figure 7.11 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
Figure 7.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 7.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 7.14 Clinical Trials Analysis: Distribution by Trial Location
Figure 7.15 Clinical Trials Analysis: Distribution by Trial Status and Geography
Figure 8.1 Academic Grant Analysis: Year-wise Distribution of Number of Grants
Figure 8.2 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded (USD Million)
Figure 8.3 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
Figure 8.4 Academic Grant Analysis: Analysis by Type of Funding Institute Center
Figure 8.5 Academic Grant Analysis: Distribution by Support Period
Figure 8.6 Academic Grant Analysis: Distribution by Purpose of Grants
Figure 8.7 Academic Grant Analysis: Distribution by Emerging Focus Area
Figure 8.8 Academic Grant Analysis: Distribution by Grant Activity Code
Figure 8.9 Academic Grant Analysis: Distribution by Local Recipients
Figure 8.10 Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.11 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount Awarded
Figure 8.12 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number of Grants
Figure 8.13 Academic Grant Analysis: Distribution by Study Section
Figure 8.14 Academic Grant Analysis: Distribution by Type of Grant Application
Figure 8.15 Academic Grant Analysis: Analysis by Funding Institute Center and Support Year
Figure 9.1 Global Events: Cumulative Half Yearly Trend, since 2019
Figure 9.2 Global Events: Distribution by Event Platform
Figure 9.3 Global Events: Distribution by Type of Event
Figure 9.4 Global Events: Distribution by Location of Event
Figure 9.5 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
Figure 9.6 Most Active Organizers: Distribution by Number of Events
Figure 9.7 Most Active Industry Participants: Distribution by Number of Events
Figure 9.8 Most Active Non-Industry Participants: Distribution by Number of Events
Figure 9.9 Global Events: Distribution by Designation of Participant
Figure 9.10 Global Events: Distribution by Affiliated Department of Participant
Figure 9.11 Most Active Speakers: Distribution by Number of Events
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2017
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, since 2017
Figure 10.4 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, since 2017
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Technology Platform
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.7 Word Cloud Analysis: Emerging Focus Areas
Figure 10.8 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Figure 10.9 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.10 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 10.11 Most Active Players: Distribution by Number of Partnerships
Figure 10.12 Partnerships and Collaborations: Regional Distribution
Figure 10.13 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Funding and Investments: Year-wise Distribution by Year of Funding, since 2017
Figure 11.2 Funding and Investments: Year-wise Distribution by Amount Invested, since 2017 (USD Million)
Figure 11.3 Funding and Investments: Distribution by Type of Funding
Figure 11.4 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, since 2017
Figure 11.5 Funding and Investments: Year-wise Distribution by Year, Type of Funding and Amount Invested, since 2017
Figure 11.6 Funding and Investments: Distribution by Purpose of Funding
Figure 11.7 Funding and Investments: Distribution by Target Disease Indication(s)
Figure 11.8 Funding and Investments: Distribution by Therapeutic Area
Figure 11.9 Most Active Players: Distribution by Number of Funding Instances
Figure 11.10 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 11.11 Key Investors: Distribution by Number of Funding Instances
Figure 11.12 Funding and Investments: Distribution by Geographical Regions
Figure 11.13 Summary of Funding Instances
Figure 12.1 Start-up Health Indexing: Distribution by Pipeline Maturity
Figure 12.2 Start-up Health Indexing: Distribution by Pipeline Strength
Figure 12.3 Start-up Health Indexing: Distribution by Financial Support
Figure 12.4 Start-up Health Indexing: Distribution by Number of Investors
Figure 12.5 Start-up Health Indexing: Distribution by Partnership Activity
Figure 12.6 Start-up Health Indexing: Roots Analysis Perspective
Figure 13.1 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Year of Establishment
Figure 13.2 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Company Size
Figure 13.3 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Location of Headquarters
Figure 13.4 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Location of Headquarters and Company Size
Figure 13.5 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Type of Service(s) Offered
Figure 13.6 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Isolation
Figure 13.7 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Purification
Figure 13.8 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Characterization
Figure 13.9 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Manufacturing
Figure 13.10 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Scale of Operation
Figure 13.11 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Scalability
Figure 14.1 Drug Failure Analysis: Distribution by Study Start Year and Year of Termination of the Clinical Trials
Figure 14.2 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
Figure 14.3 Drug Failure Analysis: Distribution by Target Disease Indication(s)
Figure 14.4 Drug Failure Analysis: Distribution by Route of Administration
Figure 14.5 Drug Failure Analysis: Distribution by Type of Sponsor
Figure 14.6 Drug Failure Analysis: Distribution by Reasons for Drug Failure
Figure 14.7 Word Cloud Analysis: Emerging Focus Area
Figure 15.1 Global Exosome Therapeutics Market, 2029-2040 (USD Million)
Figure 15.2 Global Exosome Therapeutics Market, 2029 and 2035: Distribution by Type of Target Disease Indication(s) (USD Million)
Figure 15.3 Exosome Therapeutics Market for COVID-19, 2029-2040 (USD Million)
Figure 15.4 Exosome Therapeutics Market for Retinitis Pigmentosa, 2029-2040 (USD Million)
Figure 15.5 Exosome Therapeutics Market for Degenerative Meniscal Injury, 2029-2040 (USD Million)
Figure 15.6 Global Exosome Therapeutics Market, 2029 and 2035: Distribution by Therapeutic Area (USD Million)
Figure 15.7 Exosome Therapeutics Market for Infectious Diseases, 2029-2040 (USD Million)
Figure 15.8 Exosome Therapeutics Market for Musculoskeletal Disorders, 2031-2040 (USD Million)
Figure 15.9 Exosome Therapeutics Market for Ophthalmic Diseases, 2033-2040 (USD Million)
Figure 15.10 Global Exosome Therapeutics Market, 2029 and 2035: Distribution by Route of Administration
Figure 15.11 Inhalation Exosome Therapeutics Market, 2029-2040 (USD Million)
Figure 15.12 Intravenous Exosome Therapeutics Market, 2031-2040 (USD Million)
Figure 15.13 Intra-articular Exosome Therapeutics Market, 2033-2040 (USD Million)
Figure 15.14 Intra-ocular Exosome Therapeutics Market, 2029-2040 (USD Million)
Figure 15.15 Global Exosome Therapeutics Market, 2029 and 2035: Distribution by Type of Formulation
Figure 15.16 Exosome Therapeutics Market for Liquid Formulations, 2029-2040 (USD Million)
Figure 15.17 Exosome Therapeutics Market for Aerosol Formulations, 2029-2040 (USD Million)
Figure 15.18 Global Exosome Therapeutics Market, 2029 and 2035: Distribution by Geography
Figure 15.19 Exosome Therapeutics Market in North America, 2029-2040 (USD Million)
Figure 15.20 Exosome Therapeutics Market in Europe, 2029-2040 (USD Million)
Figure 15.21 Exosome Therapeutics Market in Asia Pacific, 2030-2040 (USD Million)

Exosome Therapy Market by Type of Therapeutic, Target Indication, Therapeutic Area, Route of Administration and Geography : Industry Trends and Global Forecasts, Till 2035

Description

Table of Contents

List of Tables

EXOSOME THERAPY MARKET: OVERVIEW

EXOSOME THERAPY MARKET: GROWTH AND TRENDS

EXOSOME THERAPY MARKET: KEY INSIGHTS

EXOSOME THERAPY MARKET: KEY SEGMENTS

Example Players in the Exosome Therapy Market

Primary Research Overview

EXOSOME THERAPY MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE

5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES

6. EXOSOME THERAPEUTICS: DRUG PROFILES

7. CLINICAL TRIAL ANALYSIS

8. ACADEMIC GRANT ANALYSIS

9. GLOBAL EVENT ANALYSIS

10. PARTNERSHIPS AND COLLABORATIONS

11. FUNDING AND INVESTMENT ANALYSIS

12. START-UP HEALTH INDEXING

13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS

14. DRUG FAILURE ANALYSIS

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

16. EXECUTIVE INSIGHTS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures